Efficacy of conbercept in the treatment of central serous choroidal retinopathy by EDI-OCT / 眼科新进展

ABSTRACT

Objective To observe the efficacy and safety of conbercept in the treatment of central serous chorioretinopathy (CSC) by EDI-OCT.Methods From July 2015 to July 2017,42 patients (44 eyes) of central serous choriodal retinopathy received intravitreal injection of conbercept (0.5 mg,0.05 mL).Then,the best corrected visual acuity was recorded before injection and 1 week,4 weeks and 12 weeks after treatment;meanwhile,EDI-OCT was used to measure subfoveal choroidal thickness at different time points.Results In CSC patients,the BCVA of 1 week,4 weeks and 12 weeks after treatment were 0.57 ±0.23,0.62 ±0.23 and 0.59 ±0.71,respectively,which were significantly higher than those before treatment [(0.43 ± 1.11)] (all P ＜ 0.05).The subfoveal choroidal thickness was (308.17 ± 16.52) μm,(286.54 ± 37.52) μm and (274.58±41.38)μm at 1 week,4 weeks and 12 weeks after treatment,respectively,which were significantly lower than those before treatment [(346.31 ± 59.43) μm] (all P ＜ 0.05).Conclusion It is safe and effective for conbercept injection in the treatment of CSC.